Diethylaminoethyl Phenylbutyrate Bulk Price Global Manufacturer Analysis
- [Synthetic Fidelity]: Optimized esterification routes ensure minimal impurity profiles and high reaction yields for consistent downstream processing.
- [Sourcing Economics]: Direct factory engagement eliminates intermediary markups, stabilizing tonnage quantities against market volatility.
- [Regulatory Alignment]: Full documentation support including DMF readiness and batch-specific verification ensures seamless audit compliance.
In the competitive landscape of pharmaceutical intermediates, securing a reliable supply chain for active components is critical for commercial viability. NINGBO INNO PHARMCHEM CO.,LTD. stands as a premier global manufacturer dedicated to delivering high-purity intermediates that meet rigorous international standards. For formulators and procurement specialists evaluating the Diethylaminoethyl Phenylbutyrate Bulk Price Global Manufacturer landscape, understanding the intersection of technical specifications and commercial terms is essential.
This compound, often referenced in technical literature as Butethamate Citrate, serves as a vital intermediate in the synthesis of specific therapeutic agents. The market demand for process-scale purity requires a partner capable of maintaining batch-to-batch consistency while offering competitive commercial terms. Below, we analyze the technical parameters, pricing structures, and logistics frameworks necessary for successful integration into your supply chain.
Product Overview & Technical Specifications
For research and development teams, the chemical integrity of the intermediate dictates the success of the final API synthesis. The production process involves complex biochemical reaction processes, including esterification, crystallization, and solvent exchange. Maintaining measures to prevent pollution and cross-contamination is paramount during these stages.
Technical teams often reference the Einecs 237-671-6 identifier when validating material safety and regulatory status. Our synthesis routes are optimized to maximize reaction yields while minimizing difficult-to-remove impurities. This level of control supports a robust formulation guide for downstream users, ensuring the material acts as a reliable drop-in replacement for existing protocols.
| Parameter | Specification | Test Method |
|---|---|---|
| CAS Number | 13900-12-4 | N/A |
| Chemical Name | 2-Diethylaminoethyl 2-Phenylbutyrate Citrate Salt | N/A |
| Appearance | White to Off-White Crystalline Powder | Visual |
| Assay (HPLC) | ≥ 99.0% | Internal QC |
| Loss on Drying | ≤ 0.5% | Karl Fischer |
| Storage Conditions | Cool, dark place; tightly closed | GMP |
Wholesale Pricing Tiers and MOQ
Procurement officers analyzing the bulk price dynamics must consider the relationship between order volume and unit cost. As a dedicated global manufacturer, we structure our pricing to reward committed partnerships. The baseline Minimum Order Quantity (MOQ) is designed to accommodate both pilot-scale trials and commercial production runs.
Price variability often stems from raw material fluctuations and regulatory compliance costs. However, factory-direct engagement mitigates these risks. When sourcing high-purity 2-Diethylaminoethyl 2-Phenylbutyrate Citrate Salt, buyers should prioritize suppliers who provide transparent cost breakdowns. Every batch is accompanied by a verified COA (Certificate of Analysis), ensuring that the commercial grade material meets the specified assay requirements without hidden quality costs.
Volume Discount Structures for 2026
Executive leadership must evaluate the long-term commercial viability of their supply chain. For the 2026 fiscal period, we have implemented tiered discount structures that align with projected production scaling. These structures are designed to support clients moving from clinical phases to full-scale commercialization.
Securing pharmaceutical grade materials at locked-in rates provides a strategic advantage against market volatility. Our capacity planning allows for tonnage quantities, ensuring that sudden demand spikes do not disrupt your manufacturing timeline. By establishing a master supply agreement, executives can stabilize budget forecasting and ensure consistent availability of this critical intermediate.
Global Logistics and Lead Times
Supply chain resilience is a key performance indicator for modern pharmaceutical manufacturing. Our logistics framework supports global distribution with optimized lead times. We utilize specialized packaging to ensure the container remains tightly closed and protected from incompatible materials such as oxidizing agents during transit.
Storage instructions mandate keeping the material in a cool and dark place, and our shipping protocols reflect these requirements to maintain integrity upon arrival. Whether shipping to North America, Europe, or Asia, our compliance team ensures all documentation meets local regulatory standards, facilitating smooth customs clearance and rapid integration into your production facilities.
NINGBO INNO PHARMCHEM CO.,LTD. remains committed to supporting your development goals with reliable supply and technical expertise. To proceed, please contact our technical sales team for a batch-specific COA, SDS, or bulk pricing quote tailored to your volume requirements.